Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions

Vultaggio, Alessandra; Matucci, Andrea; Nencini, Francesca; Pratesi, Sara; Parronchi, Paola; Riggio, Oliviero; Romagnani, Sergio; Maggi, Enrico

doi:10.1111/j.1398-9995.2009.02280.x

Cited by 207 publications

(144 citation statements)

References 9 publications

(11 reference statements)

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, hypotensive severe reactions, which occur most often as early as week 6 of treatment and are unpredictable, are not bound to the production of antibodies to infliximab of group IgG1. It is assumed that in these reactions, we are dealing with anaphylactic reaction or reaction mediated by IgM antibodies to infliximab or it may be a cytokine release complex with excessive release of cytokines in the body [7,8]. It appears that even delayed infusion reactions are not bound to the production of ATI [9].…”

Section: Discussionmentioning

confidence: 99%

Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab

Kovacikova¹

2014

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab

Kovacikova¹

2014

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

“…Podaci da je kod nekih pacijenata koji su bili na terapiji infliksimabom došlo do teške anafilaktičke reakcije tokom davanja infuzije i da su oni bili pozitivni na anti-lek antitela, ali nisu imali anti-lek antitela IgE i IgM klase, ukazala su da bi mehanizmi, koji uključuju anti-lek antitela drugih klasa (prevashodno IgG klase) mogli biti odgovorni za nastalu preosetljivost (44). Naime, već je ranije pokazano na eksperimentalnom modelu kod miša da anafilaksija može biti izazvana na dva potpuno nezavisna načina.…”

Section: Posledice Prisustva Anti-lek Antitelaunclassified

Adverse side-effects of biological agents: Hypersensitivity reactions

et al. 2014

View full text Add to dashboard Cite

Kratak sadržajViše od dve decenije biološki lekovi (proteini dobijeni iz bioloških izvora, kao što su bakterije, gljive ili ćelije sisara) koriste se u terapiji različitih autoimunskih/ inflamatornih bolesti i tumora kod ljudi. Primena ovih lekova praćena je pojavom novih neželjenih efekata koji se mogu svrstati u pet različitih grupa koje se obeležavaju slovima grčkog alfabeta (od α do ε). Reakcije preosetljivosti koje se vezuju za imunogenost bioloških lekova su klasifikovane kao reakcije iz grupe tip β. U praksi, svi proteini koji se koriste kao biološki lekovi, pokreću imunski odgovor, a kao rezultat nastaju anti-lek antitela. Brojni faktori koji su vezani za sam lek, pacijenta ili način davanja leka mogu da utiču na imunogenost nekog biološkog leka. Anti-lek antitela mogu da se vežu za lek i smanje njegovu efikasnost ili da izazovu reakcije preosetljivosti (uglavnom tip I, ređe tip III). Infuzijska reakcija, koja se javlja već u toku davanja infuzije leka ili u okviru jednog sata od njenog završetka, jedna je od najčešćih reakcija preosetljivosti na biološke lekove. U ovom radu opisani su faktori koji mogu da utiču na imunogenost bioloških lekova i patogenetski mehanizmi reakcija preosetljivosti na biološke lekove.Ključne reči: imunogenost, biološki lekovi, anti-lek antitela, neželjeni efekti, monoklonska antitela

show abstract

“…Infliximab-specific antibodies are primarily IgG isotypes, although other isotypes such as IgA, IgM, and rarely IgE have been reported (34,35 ). Of the IgGtype antibodies, IgG1 and IgG4 are most common for both infliximab (34 ) and adalimumab (18,36 ).…”

Section: Ada Responsementioning

confidence: 99%

Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory

Lázár‐Molnár

Delgado

2016

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND Tumor necrosis factor (TNF) antagonists are increasingly used for the treatment of inflammatory and autoimmune diseases. Immunogenicity of these drugs poses therapeutic challenges such as therapeutic failure and adverse effects in a number of patients. Evaluation of clinical nonresponsiveness includes laboratory testing for drug concentrations and detecting the presence of antidrug antibodies. CONTENT This review provides an overview of the immunogenicity of TNF antagonists and testing methodologies currently available for measuring antidrug antibody response, which decreases treatment efficacy and may result in therapeutic failure. This review summarizes methodologies such as binding assays, including ELISA and HPLC-based homogenous mobility shift assay, as well as functional cell-based assays such as reporter gene assay. Furthermore, based on the laboratory findings of testing for antidrug antibody response, as well as serum drug concentrations, an algorithm is provided for interpretation, based on the current available literature and guidelines, which may aid in determining optimal therapy after treatment failure. SUMMARY Laboratory testing methodologies for measuring serum concentrations of TNF inhibitors and antidrug antibodies are clinically available. These methods provide an evidence-based, personalized approach for the workup of patients showing treatment failure, which saves time and resources, and contributes to improved patient care.

show abstract

Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions

Abstract: This report indicates that in some patients with infliximab-related severe reactions, IgE or IgM antibodies against infliximab were detectable. The majority of reactions could be predicted by the appearance of anti-infliximab antibodies.

Cited by 207 publications

References 9 publications

Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab

Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab

Adverse side-effects of biological agents: Hypersensitivity reactions

Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory

Contact Info

Product

Resources

About